Oxytocin vs PT-141 (Bremelanotide)

Oxytocin: The "bonding hormone" — neuropeptide with established obstetric and exploratory social roles. Typical dose 24-40 IU (intranasal) mcg. PT-141 (Bremelanotide): FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. Typical dose 1000-2000 mcg. Both fall under the Sexual Health category.

Stacking Oxytocin with PT-141 (Bremelanotide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Oxytocin is typically dosed: As needed, typically 30-45 min before relevant activity for Intranasal social/research; As needed for Subcutaneous wellness; Titrated infusion for Obstetric (clinical IV). PT-141 (Bremelanotide) is typically dosed: As needed, at least 45 minutes before activity for HSDD treatment (FDA-approved dose); As needed, 45-60 minutes before activity for General sexual function enhancement.

Oxytocin: FDA approved as injectable Pitocin for obstetric indications since the 1960s. Intranasal oxytocin not FDA-approved as therapeutic; available via compounding pharmacies. PT-141 (Bremelanotide): FDA approved. Bremelanotide (Vyleesi) was approved in June 2019 for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.